Ticker LaunchIPO · ADGI
Invivyd, Inc.
Formerly Adagio Therapeutics, Inc.
Invivyd, Inc. (ADGI) priced its initial public offering on Aug 6, 2021 at $17.00 per share, raising $309.4M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.84B. Cooley advised the company and Davis Polk advised the underwriters.
Invivyd, Inc. is a clinical-stage biopharmaceutical company developing antibody-based solutions for infectious diseases with pandemic potential. Its lead candidate, ADG20, is being developed for the treatment and prevention of COVID-19.
- Status
- IPO
- Ticker
- ADGI
- Exchange
- Nasdaq Global Market
- Priced
- Aug 6, 2021
- IPO price
- $17.00
- Raised
- $309.4M
- Market cap at IPO price
- $1.84B
- First filed
- Jul 16, 2021
- Company counsel
- Cooley
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- CT
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 16, 2021
- Latest amendment Aug 4, 2021
- Final prospectus (424B4) Aug 6, 2021
- All filings on EDGAR CIK 1832038
Other Biotech & pharma IPOs in 2021
- Climb Bio, Inc.ELYM · Aug 11, 2021 · $80M
- Omega Therapeutics, Inc.OMGA · Aug 2, 2021 · $125.8M
- Rani Therapeutics Holdings, Inc.RANI · Aug 2, 2021 · $73.3M
- Icosavax, Inc.ICVX · Jul 30, 2021 · $182M
- Immuneering CorpIMRX · Jul 30, 2021
- Maxcyte, Inc.MXCT · Jul 30, 2021